Caregiver induced Alcohol Dependence in a young child with ADHD – a case report.

A four and a half year old young boy with ADHD (attention-deficit hyperactivity disorder) was brought bysocial worker as a case of child abuse, as he was being sedated by his infirm grandfather, using alcohol, tocontrol hyperactivity. The child underwent deaddiction, treated for hyperactivity and enrolled into variousactivities. Grandfather was also extended therapeutic services. Caregiver was changed and case wasmonitored by social worker. Family was extensively given psycho education, especially regarding childabuse. Discussion of this unusual case is chiefly on ADHD, caregiver burnout, substance abuse and of coursechild abuse – its current state of under-recognition in India, detection and management.

Application of cerebrolysin in pediatric clinic / 中国生化药物杂志

Cerebrolysin is an aqueous mixture of amino acids extracted from porcine brain, and mainly composed of 85% free amino acids and 15%small peptides. Cerebrolysin increase the metabolism of amino acids and glucose transport in the brain, improve the anti-anoxia ability of cells, and to enhance the brain's resistance to various types of malignant stimulation like stress and damage. Cerebrolysin can also promote synapse formation, induce neuronal differentiation, and help reverse brain injury. Because of its efficacy and safety, cerebrolysin has been widely used in the pediatric clinical practice, and primarily to treat neonatal hypoxic ischemic encephalopathy, childcerebral palsy, hyperactivity disorder, speech communication disorders, etc.The clinical symptoms were improved to some extent after the treatment of cerebrolysin. The recovery of consciousness, enhancement of comprehensionand memory, and improvement of the extremity motor function were observed. The treatment of cerebrolysincan not only enhance the cure rate, but also reduce the incidence of sequelae. This paper systematically summarized the clinical application of cerebrolysin in the pediatric population and relevant preclinical studies, to provide more guidance for clinical application of cerebrolysin in the treatment of pediatric diseases.

Efficacy and Safety of Cerebrolysin in Adjuvant Treatment of Acute Cerebral Infarction: A Systematic Review / 中国药房

OBJECTIVE:To evaluate the efficacy and safety of cerebrolysin in adjuvant treatmenut of acute cerebral infarction systematically,and to provide evidence-based reference in clinic.METHODS:Retrieved from SCI,Cochrane Library,EMBase,PubMed,CJFD,VIP and Wanfang Database,RCTs about cerebrolysin combined with routine plan (trial group) vs.routine plan alone or combined with placebo (control group) in adjuvant treatment of acute cerebral infarction were collected.After data extraction and quality evaluation by using Cochrane systematic review manual 5.1.0,Meta-analysis was conducted by using Rev Man 5.2 statistical software.RESULTS:A total of 20 RCTs were included,involving 3 313 patients.Meta-analysis showed that NIHSS score [MD=-1.77,95％CI(-2.33,-1.21),P＜0.001],response rate [OR=2.85,95％CI(1.75,4.63),P＜0.001] and Barthel index (BI) score [MD =7.30,95 ％ CI (3.48,11.13),P＜ 0.001] in trial group were significantly higher than control group,with statistical significance.There was no statistical significance in disability rate [OR=0.46,95％ CI(0.20,1.03),P=0.06],mortality [OR=0.79,95％ CI (0.52,1.19),P=0.25],the incidence of ADR [OR=1.04,95％ CI (0.85,1.27),P=0.72] or the incidence of severe ADR [OR=0.01,95％CI(-0.02,0.04),P=0.51] between 2 groups.CONCLUSIONS:Cerebrolysin is good for adjanctive therapy of acute cerebral infarction,can significantly improve neurologic impairment and life quality and dosen't increase the incidence of ADR.

Cerebrolysin for patients with HIE:a systematic review / 中国生化药物杂志

Objective Systematic evaluation of cerebrolysin in the treatment of neonatal hypoxic -ischemic encephalopathy.Methods Computer search Cochrane Library, EMBase, PubMed, Chinese Journal Full-text Database (CNKI), Chinese Biomedical Literature Database (CBM), Wanfang Database ( each database retrieval time from its creation to May 2016 ) About cerebrolysin Randomized controlled clinical trial of neonatal hypoxic -ischemic encephalopathy.According to the inclusion and exclusion criteria of the literature, the methodological quality of the included research was evaluated and the data were extracted.Metadata was analyzed by RevMan 5.3 software.Results A total of 41 RCT patients were enrolled, with a total of 3695 patients, the experimental group was 1932 cases, the control group was 1763 cases.Meta analysis showed, the efficacy of cerebrolysin in the treatment of neonatal hypoxic-ischemic encephalopathy was significantly higher than that in the control group [OR=3.85, 95% CI (3.15,4.70), P<0.000001], for the impact of clinical symptoms, the number of primitive reflexes of neonatal hypoxic-ischemic encephalopathy in the treatment group was significantly higher than that in the control group [MD=-1.22, 95% CI ( -2.06,-0.38), P=0.004], muscle tension recovery days[MD=-1.69, 95% CI ( -1.80,-1.58), P<0.00001], conscious state recovery days[MD=-1.32, 95% CI ( -2.25,-0.40), P=0.005], seizure recovery days [MD=-2.36, 95% CI ( -3.70, -1.03), P =0.0005], and other indicators were shorter than the control group, the difference between the experimental group and the control group was statistically significant.Conclusion Cerebrolysin havean effective in treating HIE.

Neuroprotective effect of cerebrolysin in ophthalmology / 中国生化药物杂志

Cerebrolysin is an aqueous mixture of amino acids extracted from porcine brain.Cerebrolysin, contains a variety of amino acids and low molecular weight peptides, are permeable to the blood-brain barrier and blood-ocular barrier and can directly act on neurons in the CNS.As amino acid-based neuroprotective reagents, cerebrolysin can improve the neuronal metabolism, promote synapse formation and induce neuronal differentiation, and thus elicit neuroprotective efffectagainst insults such as ischemia , neurotoxins and so on.Cerebrolysin is clinicly used to treat eye diseases such as traumatic eye damage, glaucoma, optic atrophy ect.This paper systematically summarizes the studies on preclinical and clinical application of cerebrolysin in ophthalmology.

Research progress of cerebrolysin in the treatment of Alzheimer’s disease / 中国生化药物杂志

Alzheimer’s disease (AD) is a chronic degenerative disease of central nervous system.The disease onset slow,early typical performance for the decline in judgment,lack of initiative,moodiness,etc,clinical manifestations of memory loss, cognitive dysfunction based.Cerebrolysin is a akind ofneurotrophicpeptidegic mixture obtained by normalized enzymolysisof lipid-free porcine brain proteins,it is rich in various amino acids,small molecule polypeptide and various essential elements such as magnesium, phosphorus and selenium.Several studies have shown that cerebrolysin can significantly improve the memory,anxiety,fatigue,dizziness and other symptoms of AD patients.In this paper,the research progress of cerebrolysin in treatment of Alzheimer’s disease were reviewed to provide reference for the comprehensive development and clinical application of cerebrolysin .

Safety and Efficacy of Cerebrolysin in Infants with Communication Defects due to Severe Perinatal Brain Insult: A Randomized Controlled Clinical Trial

BACKGROUND AND PURPOSE: The neuroregenerative drug Cerebrolysin has demonstrated efficacy in improving cognition in adults with stroke and Alzheimer's disease. The aim of this study was to determine the efficacy and safety of Cerebrolysin in the treatment of communication defects in infants with severe perinatal brain insult. METHODS: A randomized placebo-controlled clinical trial was conducted in which 158 infants (age 6-21 months) with communication defects due to severe perinatal brain insult were enrolled; 120 infants completed the study. The Cerebrolysin group (n=60) received twice-weekly Cerebrolysin injections of 0.1 mL/kg body weight for 5 weeks (total of ten injections). The placebo group (n=60) received the same amount and number of normal saline injections. RESULTS: The baseline Communication and Symbolic-Behavior-Scale-Developmental Profile scores were comparable between the two groups. After 3 months, the placebo group exhibited improvements in the social (p<0.01) and speech composite (p=0.02) scores, with 10% and 1.5% increases from baseline, respectively. The scores of the Cerebrolysin group changed from concern to no concern, with increases of 65.44%, 45.54%, 358.06%, and 96.00% from baseline in the social (p<0.001), speech (p<0.001), symbolic (p<0.001), and total (p<0.001) scores. CONCLUSIONS: Cerebrolysin dramatically improved infants' communication especially symbolic behavior which positively affected social interaction. These findings suggest that cerebrolysin may be an effective and feasible way equivalent to stem cell therapy.

Tratamiento de la enfermedad de Alzheimer: rol de agentes neurotróficos / Alzheimer's disease treatment: neurotrophic agents role

Dementia and mainly Alzheimer's disease is a very serious and frequent clinical problem. So far, the pharmacological treatment with approved drugs has been essentially symptomatic. Although the aetiology of AD is not yet fully understood, new therapy approaches are primarily based on the amyloidal hypothesis. Unfortunately, the new drugs with amyloidal target have had difficulties to show consistence in efficacy and safety On the other hand, neurotrophic factors such as NGF and BDNF are small, versatile proteins that maintain survival and function to specific neuronal populations, for instance cholinergic neurons, on which they have a trophic and protective effect. Cerebrolysin is a peptidergic drug, approved for Alzheimer 's disease in some countries, containing biologically active peptides that exert nerve growth factor like activity and it has interesting data about pleiotropic properties of the compound. Some clinical trials with cerebrolysin have demonstrated cognitive and functional benefits when comparing with placebo. In a complex therapeutic scene appears necessary to explore with more clinical trials the neurotrophic way.

Las demencias y especialmente la enfermedad de Alzheimer (EA) se han transformado en un problema clínico muy frecuente y grave. En la actualidad, los fármacos aprobados como tratamiento convencional de esta enfermedad, han demostrado esencialmente beneficios sintomáticos. Aún cuando su etiopatogenia no ha sido completamente precisada, la mayor parte de nuevas moléculas terapéuticas investigadas están basadas en la hipótesis amiloídea, pero los resultados de los estudios no han sido suficientes o en eficacia o en seguridad. Por otra parte, se ha establecido que factores neurotróficos como NGF o BDNF, poseen propiedades neuroprotectoras de poblaciones celulares específicas como las neuronas colinérgicas, severamente afectadas en la EA. Cerebrolisina, un compuesto polipeptídico aprobado en algunos países para su uso en EA, estudiado in vitro e in vivo, ha demostrado poseer valiosas propiedades pleiotrópicas similares a neurotróficos. Asimismo, algunos ensayos clínicos randomizados han demostrado beneficios clínicos en cognición y funcionalidad al comparar con placebo. En un escenario terapéutico presente complejo para la EA, existen muchas expectativas de que nuevos estudios clínicos ratifiquen las propiedades multimodales de este agente neurotrófico.

Clinical Observation on Compound Danshen and Cerebrolysin Vial Combination Therapy in Treating Cases of Neonatal Hypoxic Ischemie Encephalopathy / 国际中医中药杂志

Objective To evaluate the clinical efficacy of compound Danshen and Cerebrolysin Vial combination therapy in treating cases of neonatal hypoxic ischemic encephalopathy(HIE).Methods 90 cases of neonatal HIE hospitalized form May 2005 to September 2006 were randomly separated into an experiment group and a control group.On the basis of conventional trigeminal supporting treatment,the experiment group was treated with additional compound Danshen and Cerebrolysin Vial combination therapy.At the end of therapeutic courses,overall effective rate was evaluated.Results The overall effective rate of the experiment group was 95.56%,comparing with a 77.78% overall effective rate in the control group.The overall effective rate of the experiment group was significantly different from the control group (P＜0.05).Conclusions Compound Danshen and Cerebrolysin Vial combination therapy was significantly effective in treating neonatal hypoxic ischemic encephalopathy.This therapy is recommendable in daily clinical treatment of HIE.

Effects of cerebrolysin on intracellular calcium in primary cultured neurons after fluid percussion injury / 中国药理学通报

Aim To investigate the changes of intracellular calcium in primary cultured neurons after fluid percussion injury under the effects of cerebrolysin.Methods The neurons of rats were divided into: normal group,FPI group and cerebrolysin group(0 h and 1 h treatment after fluid percussion injury(FPI)).The intracellular calcium([Ca2+]i) at rats neurons in 24 h and 48 h postinjury were measured by using the laser scanning confocal microscope under calcium fluorescent indicator Fluo-3/AM.Results The [Ca2+]i at rats neurons were markedly increased after 24 h postinjury compared with normal neurons and maintained the higher level after 48 h.Cerebrolysin,whenever added at 0h or 1h after FBI,could significantly decrease the rise of [Ca2+]i on 24 h postinjury,which only happened in 48 h postinjury by 1 h treatment after FPI.Conclusion Cerebrolysin has the protective effects on primary cultured rat cortical neurons of rats and has the time-window treatment.